s c i e n c e q u a l i t y i n n o v a t i o n

Transcription

1 s c i e n c e q u a l i t y i n n o v a t i o n

2 FORWARD LOOKING STATEMENTS This presentation may contain certain statements including, without limitation, the words may, plan, will, estimate, continue, anticipate, intend, expect, believe, in the process, benefits, leading to, possible, is subject to and other similar expressions which may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectations and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements. These forwardlooking statements involve risks and uncertainties including, but not limited to: our ability to market and sell our products including our novel multiplexing technologies and detection platforms; our ability to maintain any technical or product advantages; the success of our Diagnostic Tools and Services business and our intent to build near-term revenue streams from this business; the successful regulatory filing and receipt of regulatory approvals for our later stage quantitative diagnostic kits; adverse changes in general economic conditions; international risk and currency exchange fluctuations; competitor activity; technology changes; regulatory approvals and the impact of healthcare reform legislation; and, SQI's ability to raise additional funds in the future. Such statements, risks and uncertainties are detailed in the Company s ongoing filings with the securities regulatory authorities, and are available to the public at The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. 2

3 science quality innovation A DIAGNOSTIC TOOLS COMPANY OFFERING MULTIPLEXED DX TESTS AND AUTOMATED SYSTEMS TO MEET THE UNMET NEEDS OF BioPharma Drug Developers & Other Diagnostic Companies with novel tests Proven multiplexing technology more results, fewer tests run Growing list of established diagnostics and global biopharma customers Technical Superiority Very high levels of customer satisfaction ISO compliant development and manufacturing trust Achieving significant cost reductions in their core business 3

4 EXPERIENCED EXECUTIVE TEAM Name Title Previous Affiliations Andrew Morris CEO Eric Brouwer CSO Russ Peloquin VP, Sales & Marketing Aye Nyein San VP Engineering Patricia Lie VP Finance TD Canada Trust PwC Peter Lea Founder 45 Publications; 40 Patents

5 BOARD OFDIRECTORS Name Title Affiliations Clive Beddoe Gerald Connor Wilmot Matthews Chairman Board Member Board Member Hanover Group of Companies Claude Ricks Chairman, Audit Committee Eric Schneider Andrew Morris Board Member Board Member, CEO

6 MULTIPLEXING mul ti plex ---- verb ---- / məl-tē -, pleks/ -to detect multiple analytes from a single biological specimen one well one unit of effort multiple results the pain is cost, the cure is multiplexing and automated analyzers from SQI using only 15 minutes of labour, our products and systems deliver full panels of over 7,000 quantified results reducing labour costs by > 90% maintaining quality and performance in every result 6

7 SIGNIFICANT LABOUR AND TIME SAVINGS Standard ELISA (manual operation) sqidlite TM 10-X 50 Minutes / Patient 30 Seconds / Patient Save time and reduce costs, with superior technical performance 7

8 SIGNIFICANT LABOUR AND TIME SAVINGS MATH 43 plex biomarker panel 100,000 patient samples Standard ELISA (manual operation) sqidlite TM 43 samples / patient 86 if using duplicates 89,583 ELISA Kits 3,733 days of labour 1 sample / patient no duplicates needed 1,042 SQI Kits 34 days of labour on 2 sqidlites and, the sqidlite is super easy to use 8

9 Focus on Two Major Dx Markets Drug Development Testing Diagnostic Tests 50% 10% 10% 10% 40% Global Pharma $11B Gobal Biotech $14B Medium Pharma 40% 40% Global Animal Health Dx Human Molecular Dx Human Protein Dx SQD IVD - autoimmune, etc. custom and off-the-shelf tests for drug development testing safety & efficacy tests are large % of total R&D budgets & are addressable by SQI tech $11B in North America we take Dx operators existing single test products and multiplex them Human and Animal Health addressable markets Human - $4B for Dx immunoassays / $9B for Dx molecular tests in North America Animal Health - $1B consumables market 9

10 CURRENT CUSTOMERS & SALES FUNNEL Customer Count Customer Description Alternate Name / Detail Commercial Status 1 GD-Biosciences PULS 7-plex predictive panel Generating Revenue, 1 sqidlite, Second Order Shipped 2 DNA Sepsis Customer Sepsis pathogen detection Generating revenue (2 sqidlites) 3 Big Pharma PK Generating revenue (1 sqidlite under service contract) 4 Big Pharma; SQI as CRO GM-CSF Generating revenue; Prd Dev done; awaiting patient samples 5 IRX Pharma Quality Control Kits Generating review (1 sqid-x); 2 orders shipped 6 Big Biotech ; SQI as CRO ADA Generating Revenu; Prod Dev Complete; waiting for primate samples 7 Big Biotech; SQI as CRO ADA Prod Dev Complete -company sold - pause Sales Funnel Near Term Prospects 8 Direct to Consumer Dx Celiac / RA / Men's health Contracting 9 Partnership: Lung Transplant Dx 8-plex MDx and PoC MDx Green Light to proceed; Term Sheet and Quote pending acceptance 10 CRO Take out MSD - cytokines, ADA Work planning Animal Dx (same customer as #2) Bovine Mastitis Selling small volumes of kits 11 Big Biotech Cytokine Samples to be sent 0x/ X Cytokine Panel Peprotech-Stanford-SQI Work planning 13 Partnership: Lupus Nephritis Dx J Winter / 6-plex Work planning Big Pharma (same customer as #3) Xplex / Streptavidin / NAb On hold 10

11 RECENT (CUSTOMER) ANNOUNCEMENTS GD Biosciences PULS cardiac panel validation completed Feb 27 their customers include Cleveland Heartlabs (acquired by Quest), LifeLabs, Cedar Sinai, and others Global Biotech Signed Jan 17 7 Plex PULS panel for cardiac markers completed, sqidlite installed Nov 30 Global Pharma Signed Nov 20 Over-subscribed financing closes Dec 20 SQI Partners with McMaster to co-develop instant immunoassay chip Jul 24 SQI Diagnostics announces commercial contract with global biotechnology company Jul 18 SQI Sells sqid-x system to IRXTherapeutics

12 5 YEAR FINANCIAL VIEW Fiscal YE 2015 [A] 2016 [A] 2017 [A] 2018 [E] 2019 [E] # Platforms $ millions Revenue Op Expenses Cash Flow Positive Exiting

13 COMPANY SNAPSHOT TSX-V :SQD Traded on OTCQ :SQIDF Shares outstanding: 135M Warrants: 59M Stock Options: Market Cap: ~$24M Insider ownership ~ 66% 24 Jun to 24 Jan trading volume = 34M VWAP = $

14 CONTACT INFORMATION: SQI DIAGNOSTICS INC. 36 METEOR DRIVE TORONTO, CANADA M9W 1A /X229